Collegium Pharmaceutical Inc (NASDAQ:COLL) Reports Record Q2 2025 Earnings and Raises Full-Year Guidance

Collegium Pharmaceutical Inc (NASDAQ:COLL) Reports Strong Q2 2025 Earnings, Beats Estimates

Collegium Pharmaceutical Inc delivered a solid performance in the second quarter of 2025, surpassing analyst expectations on both revenue and earnings per share (EPS). The company reported record quarterly net revenue of $188.0 million, marking a 29% year-over-year increase and exceeding the consensus estimate of $184.5 million. Adjusted EPS came in at $1.68, beating the forecasted $1.65.

Key Financial Highlights

• Revenue Growth: The $188.0 million in net revenue reflects strong demand across Collegium’s product portfolio, particularly its ADHD treatment, Jornay PM, which generated $32.6 million in net revenue, up 23% year-over-year.
• Pain Portfolio Performance: The company’s pain management products, including Belbuca, Xtampza ER, and the Nucynta franchise, contributed $155.4 million, a 7% increase from the prior year.
• Profitability: Adjusted EBITDA rose 9% year-over-year to $105.1 million, while GAAP net income was $12.0 million ($0.34 diluted EPS). Non-GAAP adjusted net income reached $64.3 million ($1.68 per share).

Market Reaction

Following the earnings release, Collegium’s stock saw a pre-market gain of ~1.08%, suggesting a positive initial response from investors. However, the stock has faced some pressure in recent weeks, with declines of -3.09% over the past week and -8.07% over the past month. The mixed performance may reflect broader market conditions or profit-taking after previous gains.

Raised Full-Year Guidance

Collegium raised its 2025 financial outlook, now expecting:

• Net revenue between $745–$760 million (up from prior guidance of $735–$750 million).
• Adjusted EBITDA between $440–$455 million (up from $435–$450 million).
• Jornay PM revenue projected at $140–$145 million, up from the previous estimate of at least $135 million.

The upward revision aligns with analyst expectations for full-year revenue of $760.7 million, reinforcing confidence in the company’s growth trajectory.

Strategic Developments

• Share Repurchases: The company completed a $25 million accelerated share repurchase and announced a new $150 million buyback program through 2026.
• Leadership Changes: In May, Gino Santini was appointed Chairman of the Board, and Dr. Carlos Paya joined as a director.

Looking Ahead

For Q3 2025, analysts expect revenue of $192.9 million and EPS of $1.65. Collegium’s strong execution and raised guidance suggest it is well-positioned to meet or exceed these targets.

For more detailed earnings estimates and historical performance, visit Collegium Pharmaceutical’s earnings page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.